Tonix sublingual therapy for fibromyalgia set for Phase III; Arch Therapeutics aims to stop bleeding during surgery;

> Tonix Pharmaceuticals said it will begin the Phase III clinical trial of its sublingual reformulation of cyclobenzaprine to treat fibromyalgia in the second quarter of this year because the has FDA accepted its proposed primary outcome measure of pain reduction. The company missed a different outcome measure of pain reduction in a Phase IIb study, but appears to have convinced FDA to let it use a different proxy for pain reduction this time around. Release

> Arch Therapeutics said preclinical tests of its AC5 Surgical Hemostatic Device were positive, as it aims develop a medical device to stop bleeding during surgery based on its self-assembling peptide technology platform. Release

Suggested Articles

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.